- Home
- ORMP
as 11-21-2024 4:00pm EST
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its product pipeline includes ORMD-0801, ORMD-0801, and ORMD 0901.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 94.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 108.3K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.00 - $3.67 | Next Earning Date: | 12-03-2024 |
| Revenue: | N/A | Revenue Growth: | -50.43% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oramed Pharmaceuticals Inc. News
ORMP Breaking Stock News: Dive into ORMP Ticker-Specific Updates for Smart Investing
Simply Wall St.
16 days ago
US Penny Stocks To Watch: 3 Picks With Market Caps Over $40M
MT Newswires
a month ago
Scilex Holding Starts $50 Million Registered Direct Offering of Convertible Notes
PR Newswire
a month ago
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
MT Newswires
2 months ago
Scilex Holding to Pay $2 Million to Oramed Pharmaceuticals in Loan Accord
Zacks Small Cap Research
3 months ago
ORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, Buybacks
Associated Press Finance
3 months ago
Oramed: Q2 Earnings Snapshot
MT Newswires
5 months ago
Oramed Pharmaceuticals Board Approves $20 Million Share-Buyback Program
PR Newswire
5 months ago
Oramed Letter to Shareholders
Compare ORMP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORMP Oramed Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.